HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Roche bets $700M upfront on Nurix's late-phase BTK degrader to tee up Lilly showdown

Roche is paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg, securing a stake in a BTK degrader that is set to go head-to-head against Eli Lilly's Jaypirca in a phase 3 trial.

By FierceBiotech · Jun 8, 2026 · via FierceBiotech
Roche bets $700M upfront on Nurix's late-phase BTK degrader to tee up Lilly showdown

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
As pro-life pressure ramps up on Trump, FDA is investigating safety of abortion pill: WSJ
The WeekFiercePharma ↗
As pro-life pressure ramps up on Trump, FDA is investigating safety of abortion pill: WSJ
The FDA is going forward with an investigation into the safety of the abortion pill mifepristone, an initiativ…
Jun 8, 2026
Medicare Advantage Expansion Slows but Deepens in 2026
The WeekBriefing
Medicare Advantage Expansion Slows but Deepens in 2026
Over half of eligible Medicare beneficiaries are now in Medicare Advantage, with growth concentrated in specia…
Jun 8, 2026
Precision under pressure: Logistic solutions for nuclear medicine scalability
The WeekBioPharma Dive ↗
Precision under pressure: Logistic solutions for nuclear medicine scalability
Racing the clock: How precision logistics deliver life-saving nuclear medicine.…
Jun 8, 2026